The majority of the cost in terms of hazards, quality of life, and resource expenditure is borne by severe instances of food allergy. The conventional approach to these types has been to avoid them completely. Oral ImmunoTherapy (OIT) has lately earned a role in their management. However, in the case of severe food allergies, OIT is frequently infeasible. Different approaches to severe food allergy have lately been presented in case reports, observational studies, and prospective research. The vast majority of them make use of biology. Omalizumab has been the most extensively researched medication for severe food allergies, and its role as an adjuvant therapy for OIT is well known. Other biologics, such as dupilumab, reslizumab, and mepolizumab, have sparked interest. Toll-like receptor agonists and gene therapy using an adeno-associated virus coding for Omalizumab are both potential treatments.

Recent research is having a significant impact on clinical practice. The study examines the adjustments to the clinical approach to severe food allergies that are now accessible. It discusses the potential evolutions of biologic therapy in severe food allergies.